ClinicalTrials.gg
Not yet recruitingNCT06947109Updated Apr 27, 2025

A Clinical Study of AK139 in Healthy Subjects

A Phase 1 interventional study of Placebo and AK111 in Healthy Subjects, sponsored by Akeso. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by Akeso · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a phase I clinical study on dose escalation evaluating the safety, tolerability, PK and PD of a single dose of AK139 administered subcutaneously in healthy subjects.

Read the detailed description

This is a phase I, dose escalation clinical study aimed to evaluate the safety, tolerability, PK and PD of AK139 in healthy subjects. This study will be conducted in a dose escalation design, sequentially increasing the dosage of the drug from low to high to complete a single subcutaneous dose escalation.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Akeso is the lead sponsor of 157 studies on the registry; 67 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily agree to participate and sign an form (ICF) before any study procedures begin.
  • Male and female healthy subjects aged 18 to 55 at the time of signing the ICF.
  • Male weight ≥ 50.0kg, female weight ≥ 45.0kg; (BMI)=Weight (kg)/Height² (m²), within the range of 19.0\~26.0 kg/m².
  • Female subjects with fertility tested negative for pregnancy during the screening period.
  • The subjects are able to communicate well with the investigator and understand and comply with the requirements of this study.

Exclusion criteria

Exclusion Criteria:

  • Allergies to AK139 components and any monoclonal antibodies.
  • Positive results of confirmatory serology test for , , or syphilis at screening.
  • have participated in any drug clinical study within 3 months prior to randomization, or are still within 5 half-lives after the last administration of other drugs (whichever is longer)
  • Previously or currently suffering from any diseases of the circulatory, endocrine, neurological, digestive, respiratory, urogenital, blood, immune, psychiatric, or metabolic systems that may interfere with the test results.
  • History of parasitic infection.
  • Drug abusers or individuals with positive urine drug results during screening.
  • Have donated blood or experienced significant blood loss, received blood transfusions, or used blood products 3 months before screening.
  • Investigator assessed that it is not suitable to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (estimated)

Study arms

  • Active comparator
    AK139 regimen

    Drug: AK111

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    Monitor for a minimum of 24 hours to assess whether the safety and tolerability are acceptable according to the investigator.

  • DrugAK111

    The study will use dose escalation scheme. Before proceeding to randomize the next group of subjects, the safety data from all subjects in the previous dose group must be reviewed and confirmed.

06

What researchers measure

Primary outcomes

  1. Adverse Events (AE)

    The incidence of AEs . An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Baseline to week 12

Secondary outcomes

  1. Peak concentration (Cmax)

    Measure and assess the Cmax of AK139.

    Time frame: Week 0 to week 12

  2. Time to peak (Tmax)

    Measure and assess the Tmax of AK139

    Time frame: Week 0 to week 12

  3. Area under the curve (AUC)

    Measure and assess the AUC of AK139

    Time frame: Week 0 to week 12

  4. Half-life (t1/2)

    Measure and assess the t1/2 of AK139.

    Time frame: Week 0 to week 12

  5. Anti-drug antibody (ADA)

    Measure and assess the ADA of AK139.

    Time frame: Week 0/2/4/8/12

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Jan 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2025
First posted
Apr 27, 2025
StartEst.
May 6, 2025
Primary completionEst.
Jan 30, 2026
CompletionEst.
Jan 30, 2026
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06947109
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Apr 27, 2025
Start date
May 6, 2025 (estimated)
Primary completion
Jan 30, 2026 (estimated)
Completion
Jan 30, 2026 (estimated)
Last update
Apr 27, 2025

Study contacts

Guoqin Wang
Contact
global.trials@akesobio.com
86 (0760) 8987 3999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gumokimab

Start the discussion